Correlates of vaccine-induced protection against SARS-CoV-2
…, SC Mellinghoff, P Shamsrizi, MM Addo, C Dahlke - Vaccines, 2021 - mdpi.com
We are in the midst of a pandemic caused by the novel severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS…
coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS…
[HTML][HTML] Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens
A Fathi, MM Addo, C Dahlke - Frontiers in immunology, 2021 - frontiersin.org
Vaccines are one of the greatest public health achievements and have saved millions of
lives. They represent a key countermeasure to limit epidemics caused by emerging infectious …
lives. They represent a key countermeasure to limit epidemics caused by emerging infectious …
Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
A Fathi, C Dahlke, MM Addo - Human vaccines & …, 2019 - Taylor & Francis
The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the
need for the timely development of vaccines for high-threat pathogens. To be better prepared …
need for the timely development of vaccines for high-threat pathogens. To be better prepared …
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
…, ME Zinser, P Njuguna, C Dahlke… - … England Journal of …, 2016 - Mass Medical Soc
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
[PDF][PDF] Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease
…, L von Wenserski, R Scholz, I Wieters, C Dahlke… - Immunity, 2020 - cell.com
We profiled adaptive immunity in COVID-19 patients with active infection or after recovery
and created a repository of currently >14 million B and T cell receptor (BCR and TCR) …
and created a repository of currently >14 million B and T cell receptor (BCR and TCR) …
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
T Koch, C Dahlke, A Fathi, A Kupke… - The Lancet Infectious …, 2020 - thelancet.com
Background The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
[PDF][PDF] Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV
Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach
to identify early innate immune correlates of antibody induction in humans receiving the …
to identify early innate immune correlates of antibody induction in humans receiving the …
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
…, P Schommers, L Gieselmann, R Eggeling, C Dahlke… - Nature medicine, 2019 - nature.com
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is the most advanced
Ebola virus vaccine candidate and is currently being used to combat the outbreak of …
Ebola virus vaccine candidate and is currently being used to combat the outbreak of …
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
CM Zu Natrup, A Tscherne, C Dahlke… - The Journal of …, 2022 - Am Soc Clin Investig
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must
be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus …
be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus …
Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization
C Dahlke, R Kasonta, S Lunemann, V Krähling… - …, 2017 - thelancet.com
Background The recent West African Ebola epidemic led to accelerated efforts to test Ebola
vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (…
vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (…
